Paclitaxel Plus Bevacizumab in Patients with Chemosensitive Relapsed Small Cell Lung Cancer A Safety, Feasibility, and Efficacy Study from the Hoosier Oncology Group

被引:49
作者
Jalal, Shadia [1 ]
Bedano, Pablo
Einhorn, Lawrence [1 ]
Bhatia, Sumeet [2 ]
Ansari, Rafat [3 ]
Bechar, Naftali [3 ,4 ]
Koneru, Karuna [5 ]
Govindan, Ramaswamy [6 ]
Wu, Jingwei
Yu, Menggang
Schneider, Bryan [1 ]
Hanna, Nasser [1 ]
机构
[1] Indiana Univ, Melvin & Bren Simon Canc Ctr, Indianapolis, IN USA
[2] Community Reg Canc Ctr, Indianapolis, IN USA
[3] No Indiana Canc Res Consortium, South Bend, IN USA
[4] Community Oncol Ctr, Kokomo, IN USA
[5] Canc Care Ctr So Indiana, Bloomington, IN USA
[6] Washington Univ, Med Ctr, Siteman Canc Ctr, St Louis, MO USA
关键词
Relapsed small cell; Paclitaxel; Bevacizumab; PHASE-II; POLYMORPHISMS; CARBOPLATIN; ASSOCIATION; TRIAL;
D O I
10.1097/JTO.0b013e3181f77b6e
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: Bevacizumab when combined with carboplatin and paclitaxel improves response rates (RRs) and overall survival in patients with advanced non-small cell lung cancer. Paclitaxel has single-agent activity in relapsed small cell lung cancer (SCLC). Angiogenesis seems to play an important role in the pathogenesis of SCLC. This study evaluated the safety and efficacy of paclitaxel plus bevacizumab in patients with chemosensitive relapsed SCLC. Methods: Patients with relapsed chemosensitive SCLC with an Eastern Cooperative Oncology Group performance status of 0 to 1 were eligible. They received paclitaxel 90 mg/m(2) intravenously on days 1, 8, and 15. Bevacizumab was administered at 10 mg/kg intravenously on days 1 and 15. Cycles were every 28 days. The primary endpoint was progression-free survival (PFS). Secondary endpoints included RRs, toxicity, and overall survival. Correlative studies evaluated vascular endothelial growth factor polymorphisms. Results: Thirty-four patients were enrolled in the study. Median age was 66.5 (range, 38-88) years, male: female: 61.8%:38.2%, Eastern Cooperative Oncology Group performance status 0: 1 47.1%:52.9%. Median progression-free survival was 14.7 weeks (equivalent to historical controls). Median survival time was 30 weeks. The overall RR was 18.1%. Stable disease rate was 39.3%, and 45.4% of patients had progressive disease. No unexpected toxicities were noted, and grade 3/4 toxicities were limited to neutropenia, fatigue, and dyspnea. None of the vascular endothelial growth factor polymorphisms evaluated were significantly associated with response. Conclusions: The addition of bevacizumab to paclitaxel does not improve outcomes in relapsed chemosensitive SCLC.
引用
收藏
页码:2008 / 2011
页数:4
相关论文
共 15 条
[1]  
Dowell JE, 2004, ANTICANCER RES, V24, P2367
[2]   PHASE-II STUDY OF PACLITAXEL IN PATIENTS WITH EXTENSIVE-DISEASE SMALL-CELL LUNG-CANCER - AN EASTERN-COOPERATIVE-ONCOLOGY-GROUP STUDY [J].
ETTINGER, DS ;
FINKELSTEIN, DM ;
SARMA, RP ;
JOHNSON, DH .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (06) :1430-1435
[3]   Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: Analysis of the surveillance, epidemiologic, and end results database [J].
Govindan, Ramaswamy ;
Page, Nathan ;
Morgensztern, Daniel ;
Read, William ;
Tierney, Ryan ;
Vlahiotis, Anna ;
Spitznagel, Edward L. ;
Piccirillo, Jay .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (28) :4539-4544
[4]   Phase II Study of Cisplatin Plus Etoposide and Bevacizumab for Previously Untreated, Extensive-Stage Small-Cell Lung Cancer: Eastern Cooperative Oncology Group Study E3501 [J].
Horn, Leora ;
Dahlberg, Suzanne E. ;
Sandler, Alan B. ;
Dowlati, Afshin ;
Moore, Dennis F. ;
Murren, John R. ;
Schiller, Joan H. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (35) :6006-6011
[5]   Paclitaxel and G-CSF in previously untreated patients with extensive stage small-cell lung cancer - A phase II study of the North Central Cancer Treatment Group [J].
Kirschling, RJ ;
Grill, JP ;
Marks, RS ;
Kugler, JW ;
Gerstner, JB ;
Kuross, SA ;
Michalak, JC ;
Windschitl, HE ;
Krewer, KD ;
Jett, JR .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1999, 22 (05) :517-522
[6]   Small cell lung carcinoma (SCLC): the angiogenic phenomenon [J].
Lucchi, M ;
Mussi, A ;
Fontanini, G ;
Faviana, P ;
Ribechini, A ;
Angeletti, CA .
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2002, 21 (06) :1105-1110
[7]   Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer [J].
Miller, Kathy ;
Wang, Molin ;
Gralow, Julie ;
Dickler, Maura ;
Cobleigh, Melody ;
Perez, Edith A. ;
Shenkier, Tamara ;
Cella, David ;
Davidson, Nancy E. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (26) :2666-2676
[8]   Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer [J].
Noda, W ;
Nishiwaki, Y ;
Kawahara, M ;
Negoro, S ;
Sugiura, T ;
Yokoyama, A ;
Fukuoka, M ;
Mori, K ;
Watanabe, K ;
Tamura, T ;
Yamamoto, S ;
Saijo, N .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (02) :85-91
[9]  
Ready N, 2007, J CLIN ONCOL, V25
[10]   Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer [J].
Sandler, Alan ;
Gray, Robert ;
Perry, Michael C. ;
Brahmer, Julie ;
Schiller, Joan H. ;
Dowlati, Afshin ;
Lilenbaum, Rogerio ;
Johnson, David H. .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (24) :2542-2550